2025/03/31
Shanghai, China – March 31, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China, successfully passed U.S. Food and Drug Administration (FDA) inspections back-to-back in March — both without a single observation and with no Form 483 issued. These achievements further demonstrate WuXi AppTec’s unwavering commitment to upholding the highest quality standards and to supporting global healthcare innovators in reliably delivering needed therapies to patients worldwide.
Read more2025/03/17
(SHANGHAI, March 17, 2025) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the year ending December 31, 2024 (“Reporting Period”).
Read more2025/03/12
SHANGHAI, March 12, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been recognized as a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, ranking in the top 1% of the pharmaceutical industry. This marks the third consecutive year that WuXi AppTec has received these prestigious distinctions, reflecting the company’s commitment to upholding high standards in Environmental, Social and Governance (ESG) initiatives.
Read more2025/03/03
SHANGHAI, March 3, 2025 – WuXi AppTec has completed the sale of its U.S. medical device testing operations to NAMSA, a Toledo, Ohio-based testing, clinical and regulatory consulting firm, which was announced on January 17, 2025. All other WuXi AppTec operations are unchanged.
Read more2025/01/17
SHANGHAI, January 17, 2025 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has entered into a definitive agreement to sell its U.S. medical device testing operations to NAMSA, a Toledo, Ohio-based MedTech testing, clinical and regulatory consulting firm.
Read more